Pulse therapy with the oral antifungal agent itraconazole for onychomycosis appears to be safe. In particular, it does not threaten liver damage, despite some reports of hepatitis. Researchers at the University of Nevada, Las Vegas, United States, the University of Toronto, Canada, and in France investigated the drug’s safety because of the increasing use of newer oral antifungal agents to treat superficial fungal infections.
The researchers noted that itraconazole was effective and well tolerated with mostly minor and reversible side-effects. The most common adverse events were gastrointestinal upset, headache, and transient skin reaction. However, there had been rare reports of hepatitis. To assess the hepatic safety of pulse and continuous itraconazole, the researchers analysed all itraconazole clinical trials sponsored by Janssen Research Foundation in the treatment of onychomycosis where there had been an assessment of laboratory safety.
They also reviewed published literature to assess the hepatic safety of itraconazole in common practice.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!